Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CVM
vs
S&P 500
S&P 500
Over the past 12 months, CVM has underperformed S&P 500, delivering a return of -80% compared to S&P 500's +10% growth.
Stocks Performance
CVM vs S&P 500
Performance Gap
CVM vs S&P 500
Create a free account · No card needed
Performance By Year
CVM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CEL-SCI Corp
Glance View
CEL-SCI is a biotechnology company focused on developing cancer treatments that help the immune system fight tumors. Its best-known product candidate is Multikine, an immune-based therapy designed for patients with advanced head and neck cancer before they receive standard surgery, radiation, or chemotherapy. The company also has other early-stage immunotherapy research, but its core identity is tied to this one lead drug program. CEL-SCI does not sell a broad line of commercial medicines like a large drugmaker. It mainly spends money on research, clinical trials, and the regulatory work needed to get a new therapy approved. If its lead program succeeds, the company would make money by selling or partnering its treatment with hospitals, cancer centers, or a larger pharmaceutical company that could help market and distribute it. What makes CEL-SCI different is its role as a drug developer rather than a drug manufacturer or distributor. It is trying to move one specialized therapy through the high-risk, highly regulated path from lab research to patient use. That makes the business much more dependent on clinical trial results and regulatory decisions than on steady product sales.